

## For Health Professionals Who Care For Cancer Patients

### Inside This Issue:

- **Editor's Choice – New Programs:** First-Line Therapy of Advanced Melanoma with Ipilimumab, Lanreotide for Growth Hormone Secreting Pituitary Adenoma
- **Cancer Drug Manual – New:** Carfilzomib Revised: Octreotide, Temozolomide
- **Benefit Drug List – New:** Ipilimumab, Lanreotide Deleted: Dexrazoxane
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts – New:** CNLAN, USMAVFIPI
- **CNLAN Revised:** BRAVABR, BRAVGEMP, GIFOLFIRI, GIGAVTR, UGUPCABA, UHNLACETRT, HNLAPRT, LKAMLCYT, UMYBORPRE, UMYBORREL, UMYLENDEX, UMYMPBOR, UMYPOMDEX Neoadjuvant Use Added to Eligibility in Breast Protocols: BRAJANAS, BRAJEXE, BRAJLET, UBRAJLHRHA, BRAJLHRHT, BRAJTAM
- **Website Resources and Contact Information**

## EDITOR'S CHOICE

### NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following programs effective 1 July 2015:

#### Melanoma:

##### **Ipilimumab for the First-Line Treatment of Advanced and Metastatic Melanoma (USMAVFIPI) –**

Ipilimumab is now available as first line monotherapy treatment option for patients with unresectable stage III or stage IV melanoma. Previously, patients would be treated with ipilimumab following prior systemic therapy. This is based on the findings in one phase III trial which showed significant survival advantage from the addition of ipilimumab to dacarbazine (median survival 11.2 vs. 9.1 mo, HR 0.72) compared to Dacarbazine alone. [Robert et al. *NEJM* 2011;364:2517-26] In addition, a pooled analysis of randomized and observation studies suggests that ipilimumab monotherapy should be effective in the first-line setting, with survival curves in previously untreated patients similar to those who received ipilimumab as subsequent therapy. [Drummer et al. *J Transl Med* 2014; ;12(Suppl 1):P8] A BCCA Compassionate Access Program (CAP) approval is required for each patient.

#### Neuro-Oncology:

- **Lanreotide for the Treatment of Pituitary Adenoma (CNLAN) –** Intramuscular octreotide is the standard long-acting drug therapy for patients with growth hormone secretion related to pituitary adenoma (CNOCTLAR). Subcutaneous lanreotide is another long-acting analog with a similar efficacy in controlling symptoms and biochemical markers associated with growth hormone secretion. It offers an alternative to long-acting octreotide for patients who are not candidates for intramuscular injection.

## CANCER DRUG MANUAL

### NEW MONOGRAPH

**Carfilzomib Interim Monograph** has been completed. This is a second generation proteasome inhibitor for the treatment of patients with relapsed or refractory multiple myeloma after prior therapy with bortezomib and thalidomide or lenalidomide. Compared to bortezomib, carfilzomib has a more selective and irreversible inhibition of the proteasome. Carfilzomib is administered intravenously on two consecutive days each week for three weeks in a 28-day cycle. The most serious hematologic toxicities are thrombocytopenia, anemia and neutropenia. Other common side effects include fatigue, nausea, dyspnea, diarrhea and pyrexia. Carfilzomib is not a BCCA benefit drug and is currently available in Canada only through the Health Canada Special Access Programme.

### REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

**Octreotide Monograph:**

- *Intramuscular administration* – added option of starting long acting formulation without first initiating therapy with short acting octreotide

**Temozolomide Monograph:**

- *Solution Preparation and Stability* – added information on compounding temozolomide suspension

## BENEFIT DRUG LIST

### NEW PROGRAMS

The following programs have been added to the [Benefit Drug List](#) effective 1 July 2015:

Protocol Title	Protocol Code	Benefit Status
First-line treatment of unresectable or metastatic melanoma using <i>ipilimumab</i>	USMAVFIPI	Restricted
Treatment of growth hormone secreting pituitary adenoma using <i>lanreotide</i>	CNLAN	Class I

## BENEFIT DRUG LIST

### DELETED PROGRAMS

The following program has been removed from the Benefit Drug List effective 1 July 2015:

Indication	Drug
Pediatric patients with osteosarcoma treated on the COG AOST0331 study	<b>Dexrazoxane</b>

## LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

### NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
CNLAN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Growth Hormone Secreting Pituitary Adenoma Using Lanreotide
USMAVFIPI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	First-line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

### REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVABR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Palliative Therapy for Metastatic Breast Cancer Using Nanoparticle, Albumin-Bound (nab)-PACLitaxel (ABRAXANE®)
BRAVGEMP	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Prochlorperazine dosing clarified</i>	Palliative Therapy for Metastatic Breast Cancer Using CISplatin and Gemcitabine
GIFOLFIRI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Minor typo corrected</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
GIGAVTR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Brand name trastuzumab added</i>	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using Trastuzumab (HERCEPTIN)
UGUPCABA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Number of treatment cycles updated</i>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Cabazitaxel and predniSONE
HNLAPRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Combined Chemotherapy CISplatin and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

**REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UHNLCETR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility clarified, magnesium supplement and rash management added</i>	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
LKAMLCYT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy of Acute Myeloid Leukemia Using Low Dose Cytarabine
UMYBORPRE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Requirement for CBC tests clarified</i>	Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant
UMYBORREL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Requirement for CBC tests clarified</i>	Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide
UMYLENDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dexamethasone dosing reduced</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone
UMYMPBOR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Requirement for CBC tests clarified</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib With the Option of Substituting Cyclophosphamide for Melphalan
UMYPOMDEX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Choice of capsule strengths clarified</i>	Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone

The title and eligibility of these breast protocols have been clarified to include their use in neoadjuvant setting without CAP application:

CODE	Protocol Title
BRAJANAS	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Anastrozole in Postmenopausal Women
BRAJEXE	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Exemestane in Postmenopausal Women
BRAJLET	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Letrozole in Postmenopausal Women
UBRAJLHRHA	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and an Aromatase Inhibitor
BRAJLHRHT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and Tamoxifen
BRAJTAM	BCCA Protocol Summary for Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen

## WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>
Systemic Therapy Update	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update</a>
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
Cancer Drug Manual	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual</a>
Cancer Management Guidelines	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines</a>
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols">www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols</a>
Systemic Therapy Program Policies	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
CON Pharmacy Educators	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy">www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy</a>

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
To update the contact information of any CON sites, please contact:			<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604.877.6275		<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Education Resource Nurse	604.877.6000 x 672638		<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604.877.6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Nursing Professional Practice	604.877.6000 x 672623		<a href="mailto:ilundie@bccancer.bc.ca">ilundie@bccancer.bc.ca</a>
OSCAR	888.355.0355	604.708.2051	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a>
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a>
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

## EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)  
 Victoria Kletas, MSc (Clin Pharm)  
 Caroline Lohrisch, MD  
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS  
 Ava Hatcher, RN, BN, CON(c)  
 Rob Watt, BSc (Pharm)